SB 688-FN (2020): relative to the pricing of generic prescription drugs.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA
“SB 688-FN (2020): relative to the pricing of generic prescription drugs.” Granite Record, https://graniterecord.org/bill/2020/sb688. Accessed 24 Oct. 2026.
APA
Granite Record. (n.d.). SB 688-FN (2020): relative to the pricing of generic prescription drugs. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2020/sb688
Chicago
Granite Record. “SB 688-FN (2020): relative to the pricing of generic prescription drugs.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2020/sb688.
BibTeX
@misc{bill-2020-sb688, title = {SB 688-FN (2020): relative to the pricing of generic prescription drugs.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2020/sb688}, note = {Accessed 24 Oct. 2026} }

SB 688-FN (2020)

relative to the pricing of generic prescription drugs.

  • Status: Died on the table
  • Term: 2019-2020
  • Senate committee: Commerce
  • Subject: Miscellaneous

The Story

It was introduced on January 8, 2020 and referred to the Senate Commerce committee. The committee held a public hearing on January 21, 2020. The committee recommended that the Senate pass it with changes (amendment 2020-1065s). The committee's amendment (2020-1065s) was adopted on a voice vote on March 11, 2020, changing the text of the bill. On March 11, 2020 the Senate voted to pass it with changes and ordered it to a third reading. On March 12, 2020 the Senate adopted “Reconsider the following action taken by this Body: Rescind Order to Third Reading and Final Passage, and Reconsider the Vote on Ought to Pass with Amendment” on a voice vote, on a motion by Sen. Feltes. On March 12, 2020 the Senate voted to pass it with changes and ordered it to a third reading.

Sponsors

Hearings and Sessions

  • January 21, 2020, 1:15 PM: hearing, Senate Commerce, SH 100

Votes

  • March 11, 2020, Senate: Ought to Pass with Amendment — yeas 14, nays 10, passed
  • March 12, 2020, Senate: Reconsider the following action taken by this Body: Rescind Order to Third Reading and Final Passage, and Reconsider the Vote on Ought to Pass with Amendment — voice vote, passed
  • March 12, 2020, Senate: Ought to Pass with Amendment — yeas 24, nays 0, passed

The Docket

  • January 8, 2020: Introduced 01/08/2020 and Referred to Commerce
  • January 21, 2020: Hearing: 01/21/2020, Room 100, SH, 01:15 pm
  • March 11, 2020: Committee Report: Ought to Pass with Amendment #2020-1065s , 03/11/2020
  • March 11, 2020: Committee Amendment #2020-1065s , AA, VV; 03/11/2020
  • March 11, 2020: Ought to Pass with Amendment 2020-1065s, RC 14Y-10N, MA; OT3rdg; 03/11/2020
  • March 12, 2020: Sen. Feltes Moved to Reconsider the following action taken by this Body: Rescind Order to Third Reading and Final Passage, and Reconsider the Vote on Ought to Pass with Amendment , MA, VV; 03/12/2020
  • March 12, 2020: Ought to Pass with Amendment 2020-1065s, RC 24Y-0N, MA; OT3rdg; 03/12/2020
  • June 30, 2020: Introduced and Laid on Table MA VV 06/30/2020
  • September 23, 2020: Died on Table

Laws It Would Change

Related Bills

  • HB 1280-FN (2020): relative to copayments for insulin, establishing a wholesale prescription drug importation program, establishing a New Hampshire prescription drug affordability board, establishing the prescription drug competitive marketplace, relative to the pricing of generic prescription drugs, relative to prior authorization for prescription drug coverage, and requiring insurance coverage for epinephrine auto-injectors.

From the General Court